Actively Recruiting
Preoperative Ultra-Hypofractionated Radiotherapy Followed by Surgery for Retroperitoneal Soft Tissue Sarcoma
Led by Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Updated on 2025-12-11
50
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the feasibility and peri-operative complications of preoperative ultra-hypofractionated radiotherapy followed by surgery in patients with retroperitoneal sarcoma, a type of soft tissue cancer located in the retroperitoneal or infra-peritoneal pelvic spaces. The study aims to understand how this treatment approach may impact surgical outcomes and complications shortly after surgery. Participants will receive ultra-hypofractionated stereotactic ablative radiotherapy, delivering a total dose of 25 to 50 Gy in five fractions before surgery. Surgery is then performed one to two months after completing the radiotherapy. This approach focuses radiation on the tumor area safely included within one radiotherapy field, avoiding involvement of critical nearby structures. During the study, participants will be closely monitored for complications from surgery up to seven days post-operation. Researchers will assess peri-operative safety and treatment feasibility. Participants must have normal kidney, bone marrow, and liver function and meet certain health and performance status criteria. The overall study duration includes radiotherapy, surgery, and the immediate postoperative monitoring period.
CONDITIONS
Brief Title
Preoperative Ultra-hypofractionated Radiotherapy Followed by Surgery for Retroperitoneal Sarcoma (FUSION-01)
Research Team
N
Ning-Ning Lu
S
Shu-Lian Wang
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here